Efinopegdutide Reconstitution Calculator
Enter the amount you want to measure. The vial buttons will highlight which vial strengths create cleaner syringe-unit measurements.
What amount do you need?
Type the target amount, then choose mg or mcg. Example: 2mg or 500mcg.
Syringe size:
Possible vial strengths:
Best Match
Good Match
Usable
Harder to Measure
Example Efinopegdutide Titration Schedule
| Parameter | Details |
|---|---|
| Dosage | 2.4 mg → 5 mg (Week 4) → 10 mg (Week 8) target; Phase 2b: 4 mg, 7 mg, or 10 mg once weekly |
| Route | Subcutaneous (SC) injection |
| Frequency | Once weekly (Q1W) |
| Cycle Length | 24 to 52 weeks (clinical trials) |
| Half‑life | Prolonged (PEG‑modified / Fc-fusion protein) |
| Reconstitution | 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% saline (research use) |
Possible vial strengths:
What Is It?
Efinopegdutide
GLP-1 / glucagon dual agonist in metabolic research.
Bacteriostatic Water
Sterile water containing a bacteriostatic preservative, commonly used when preparing multi-use research vials.
How To Mix Efinopegdutide
1
CleanUse alcohol swabs to clean the tops of both vials.
2
Draw BAC WaterDraw the selected amount of bacteriostatic water.
3
Inject SlowlyAdd the liquid slowly down the side of the vial.
4
Swirl GentlyDo not shake. Swirl gently until dissolved.
5
Store ProperlyStore as directed and protect from heat and light.
Best Practices & Common Mistakes
Best Practices
- Use sterile technique.
- Protect from light and heat.
- Store refrigerated when appropriate.
- Use clean syringe-unit math before measuring.
Common Mistakes
- Confusing milligrams with milliliters.
- Choosing an option with awkward decimal units.
- Using too little liquid for very small measurements.
- Shaking the vial aggressively.
Efinopegdutide Storage & Handling
Lyophilized Powder: −20°C (−4°F) for long-term storage (up to 24 months). Refrigeration 2–8°C (36–46°F) for short-term use (up to ~3 months). Original sealed vial in the freezer is safest.
Reconstituted Solution: 2–8°C (36–46°F), use within ~7–14 days. Keep sealed, avoid light, and do not repeat freeze-thaw cycles.
Reconstituted Solution: 2–8°C (36–46°F), use within ~7–14 days. Keep sealed, avoid light, and do not repeat freeze-thaw cycles.
Frequently Asked Questions
Efinopegdutide is an investigational GLP-1/glucagon receptor co-agonist, which means it targets two metabolic hormone pathways at once. Search interest around it is tied strongly to liver fat, NASH/MASH research, and metabolic disease rather than only scale weight.
Efinopegdutide was originally developed by Hanmi and later licensed to Merck for development in NASH/MASH. Older or technical sources may call it HM12525A or MK-6024, so a calculator page should connect all names clearly for readers.
Efinopegdutide has FDA Fast Track designation for NASH, but Fast Track is not the same as approval. Current public trial records center on Phase 2 and Phase 2b studies, so a Phase 3 search should be handled as pipeline curiosity rather than confirmed approved-drug information.
Some efinopegdutide studies compare it with semaglutide because researchers want to understand whether adding glucagon receptor activity changes liver-fat outcomes. That comparison is about clinical research design, not a claim that efinopegdutide is interchangeable with approved semaglutide products.
For research math only, concentration equals peptide amount divided by final liquid volume. For example, if 20 mg of efinopegdutide research material were brought to a final volume of 2 mL, the concentration would be 10 mg/mL; a 4 mg research amount would equal 0.40 mL, or 40 units on a U-100 scale. This is calculator math only, not a dosing protocol.
Practical takeaway: If your real goal is weight or metabolic health, the most useful next step is discussing approved treatment options with a clinician rather than relying on an unapproved compound.
Important: This tool is for informational and research-reference purposes only. Not intended for human or veterinary use.